Literature DB >> 8697641

Tyrosinase as an autoantigen in patients with vitiligo.

E Baharav1, O Merimski, Y Shoenfeld, R Zigelman, B Gilbrud, G Yecheskel, P Youinou, P Fishman.   

Abstract

Vitiligo is considered an autoimmune disorder due to the generation and presence of autoantibodies directed against melanocyte antigens in the patients' sera. In the present study we point towards a newly defined autoantigen in vitiligo, the enzyme tyrosinase, which participates in the process of melanogenesis. Anti-tyrosinase antibodies were detected in the sera of seven patients with diffuse and 11 patients with localized vitiligo. Employing solid-phase ELISA to mushroom tyrosinase, we found that patients with diffuse vitiligo had significantly higher titres of IgG anti-tyrosinase autoantibodies than patients with localized disease or healthy subjects. These anti-tyrosinase autoantibodies have relatively high functional affinity to tyrosinase and can be recovered from vitiligo patients' sera by affinity purification. The anti-tyrosinase antibodies do not cross-react with other enzymes recognized as autoantigens in different autoimmune disorders and the autoantibodies do not block the enzymatic activity of tyrosinase, indicating that they are not reacting with the catalytic site of the enzyme. These data point to tyrosinase as an autoantigen in vitiligo and suggest that anti-tyrosinase titres can serve as a marker for disease activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697641      PMCID: PMC2200479          DOI: 10.1046/j.1365-2249.1996.d01-727.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  New treatment modalities for vitiligo: focus on topical immunomodulators.

Authors:  Kresimir Kostovic; Aida Pasic
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.

Authors:  E Helen Kemp; Elizabeth A Waterman; Brian E Hawes; Kim O'Neill; Raju V S R K Gottumukkala; David J Gawkrodger; Anthony P Weetman; Philip F Watson
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

3.  Increased level of serum Homocysteine in vitiligo.

Authors:  Suman Singh; Usha Singh; Shyam Sunder Pandey
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

4.  Prevalence of choroidal nevus and retinal pigment epithelial alterations in vitiligo patients.

Authors:  Efrat Fleissig; Mor Pavlovksy; Anat Loewenstein; Dinah Zur; Hadas Newman; Shay Keren; Dafna Goldenberg; Efrat Bar-Ilan; Michaella Goldstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-16       Impact factor: 3.117

5.  The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value.

Authors:  Beatrix Kotlan; Gabriella Liszkay; Miri Blank; Orsolya Csuka; Timea Balatoni; Laszlo Toth; Klara Eles; Szabolcs Horvath; Gyorgy Naszados; Judit Olasz; Balazs Banky; Jozsef Toth; Maria Godeny; Francesco M Marincola; Miklos Kasler; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

6.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 7.  The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions.

Authors:  O Merimsky; Y Shoenfeld; P Fishman
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

8.  Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

Authors:  E A Waterman; E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 9.  Stability in Vitiligo: Is there a Perfect Way to Predict it?

Authors:  Kanika Sahni; Davinder Parsad
Journal:  J Cutan Aesthet Surg       Date:  2013-04

10.  Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo.

Authors:  Marija Dorđić; Ivana Z Matić; Ivana Filipović-Lješković; Radan Džodić; Miomir Sašić; Aleksandra Erić-Nikolić; Ana Vuletić; Branka Kolundžija; Ana Damjanović; Nađa Grozdanić; Srđan Nikolić; Janko Pralica; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Zorica Juranić
Journal:  BMC Complement Altern Med       Date:  2012-07-26       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.